Euglycemic DKA: How Ketoacidosis Happens With Normal Blood Sugar
Most people with diabetes learn one rule about diabetic ketoacidosis: it comes with very high blood sugar. Usually it does. But in about one case in ten, glucose is under 200 mg/dL when someone arrives at the hospital with DKA — and that ordinary-looking number is exactly what lets it get missed.
This article is general education, not medical advice. If you feel unwell and are worried about DKA, check ketones and contact your care team or emergency services. Do not wait for your glucose to tell you it is serious.
What DKA Actually Is
DKA is a shortage of insulin, not a surplus of sugar. Without enough insulin, your cells cannot use glucose for fuel, so your body breaks down fat instead. That produces ketones. A few are harmless; a flood of them turns the blood acidic, and that acidosis is what makes DKA dangerous.
High glucose usually travels with it, because the same insulin shortage that releases ketones also lets glucose pile up in the blood. But the two are not locked together. Your glucose depends on how much is coming in and how much is leaving the body. Your ketones depend on how short of insulin you are. Change the first without fixing the second, and you get ketoacidosis at a glucose level that looks fine.
What Counts as Euglycemic
Euglycemic DKA means the ketones and acidosis of DKA with plasma glucose under 200 mg/dL (11.1 mmol/L). Roughly 10% of people with DKA arrive this way. It is common enough that the 2024 international consensus on hyperglycemic crises changed how DKA is diagnosed: it now counts glucose above 200 mg/dL or a known history of diabetes, whatever the glucose reading.
Who Is at Risk
The 2024 consensus lists the main causes:
- SGLT2 inhibitors. These tablets, such as empagliflozin (Jardiance), dapagliflozin (Farxiga) and canagliflozin (Invokana), lower glucose by flushing it out in urine. In recent years they have accounted for the majority of euglycemic DKA cases.
- Eating very little — fasting, a very low carbohydrate intake, or not eating through an illness.
- Pregnancy.
- Alcohol and liver disease, both of which reduce how much glucose the liver produces.
- Insulin you have already taken. A dose can bring glucose down without being enough to switch off ketone production.
On type 1 diabetes, the consensus is direct: SGLT2 inhibitor therapy is not recommended. People with type 1 have been prescribed them off-label — seven of the nine people in an early case series in Diabetes Care had type 1 — and the authors of that series concluded they should be used in type 1 only with great caution, extensive counseling and close monitoring.
Why It Gets Missed
Everything about euglycemic DKA looks like something milder. You feel sick and nauseous, maybe achy and tired. You check your glucose and it says 160. Nothing about that number says emergency, so the obvious conclusion is a stomach bug.
That is not hypothetical. In the case series that first drew wide attention to SGLT2-related euglycemic DKA, the authors noted that the absence of significant hyperglycemia delayed recognition of the emergency — by patients and by their doctors.
The Symptoms
The symptoms are the same as ordinary DKA, without the high glucose reading that would normally make someone check:
- Nausea, vomiting or stomach pain
- Feeling generally unwell, tired or weak
- Thirst and signs of dehydration
- Deep or fast breathing
- Breath with a fruity smell
- Confusion or unusual drowsiness
Check Ketones, Not Just Glucose
The practical lesson is simple: when you feel ill, your ketone level tells you more than your glucose does. Check ketones whenever you are vomiting, cannot eat, or feel unwell in a way you cannot explain, even if your glucose looks normal. If you take an SGLT2 inhibitor, the case series recommends prompt testing for ketones if you develop nausea, vomiting or general malaise.
Blood ketone meters measure beta-hydroxybutyrate, the main ketone in DKA. In the 2024 consensus, a level of 3.0 mmol/L or higher identified DKA with more than 90% sensitivity and specificity. That level, or large ketones on a urine strip, means emergency care, not waiting it out. Lower but rising readings mean following your sick-day plan and calling your care team.
If you use an insulin pump, rising ketones are also a reason to suspect your infusion site. A pump delivers only rapid-acting insulin, and the ADA notes that infusion set problems — a dislodged or blocked set — put pump users at risk of ketosis and DKA.
If You Take an SGLT2 Inhibitor
None of this means these medicines are bad. For people with type 2 diabetes they are recommended to protect the kidneys and reduce heart failure hospitalizations, and many people benefit from them. It means knowing the risk. Ask whoever prescribes yours:
- What to do with it when you are sick, cannot eat, or are having surgery
- Whether you should keep a blood ketone meter at home
- Which symptoms should make you check ketones even when your glucose is fine
If you have type 1 diabetes and have been prescribed one, raise the 2024 consensus recommendation with your care team directly.
Where SweetLife Fits
SweetLife cannot measure ketones, and no app replaces a ketone meter when you feel ill. What it can do is keep the context in one place: your readings, the insulin you have logged and what you have eaten, so it is easy to see if a dose was missed or you have barely eaten all day. The emergency card keeps your insulin, allergies and notes — a good place to record an SGLT2 inhibitor — for anyone who needs to act for you.
The Short Version
DKA is an insulin shortage, and glucose does not always reveal it. About one DKA case in ten comes with glucose under 200 mg/dL, most often linked to SGLT2 inhibitors, eating very little, pregnancy or alcohol. If you feel sick, nauseous or short of breath, check ketones whatever your glucose says. A blood ketone level of 3.0 mmol/L or more is an emergency.
For the wider picture of staying safe while ill, see our guide to diabetes sick day rules.
Sources
- Umpierrez GE, Davis GM, ElSayed NA, et al. Hyperglycemic Crises in Adults With Diabetes: A Consensus Report. Diabetes Care. 2024;47(8):1257–1275. doi.org/10.2337/dci24-0032
- Peters AL, Buschur EO, Buse JB, et al. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition. Diabetes Care. 2015;38(9):1687–1693. doi.org/10.2337/dc15-0843
- American Diabetes Association Professional Practice Committee. 7. Diabetes Technology: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S126–S144. doi.org/10.2337/dc24-S007
- American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management; 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S179–S230. doi.org/10.2337/dc24-S010, doi.org/10.2337/dc24-S011
Medical Disclaimer: This article is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or qualified healthcare provider with any questions about a medical condition or changes to your diabetes management plan, including medication, insulin dosing, and pre-bolusing timing. SweetLife is a tracking and logging tool, not a medical device, and does not provide medical advice.